New combo aims to reduce dangerous side effect in blood cancer patients
NCT ID NCT04981912
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This early-phase study tests whether giving rituximab and high-dose steroids before venetoclax can safely lower the number of cancer cells in people with relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to reduce the risk of tumor lysis syndrome, a serious side effect from rapid cancer cell breakdown. About 4 adults who have already tried at least one prior treatment will participate. The approach is experimental, though all drugs are FDA-approved for these cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.